High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation

被引:5
作者
Sumransub, Nuttavut [1 ]
Cao, Qing [2 ]
Wangen, Rose [3 ]
Brunstein, Claudio [3 ]
Miller, Jeffrey S. [3 ]
Bachanova, Veronika [3 ]
机构
[1] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Clin & Translat Sci Inst, Biostat & Informat, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Div Hematol Oncol & Transplantat, Dept Med, 420 Delaware St SE,MMC 480, Minneapolis, MN 55455 USA
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2022年 / 28卷 / 04期
基金
美国国家卫生研究院;
关键词
Immune reconstitution; Autologous hematopoietic stem; cell transplantation; Regulatory T cells; Non-Hodgkin lymphoma; PREDICTS SUPERIOR SURVIVAL; INFUSED AUTOGRAFT LYMPHOCYTE; NON-HODGKIN-LYMPHOMA; EFFECTOR-CELLS; MONOCYTE RATIO; GRAFT CONTENT; RECOVERY; CHEMOTHERAPY; TREG; RECONSTITUTION;
D O I
10.1016/j.jtct.2022.01.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autologous hematopoietic cell transplantation (AHCT) in lymphoma is well established and yields improved survival for patients with chemotherapy-sensitive disease. The patterns of immune cell reconstitution after AHCT have emerged as independent predictors of clinical outcomes. We sought to analyze the patterns of regulatory T cell (Treg) reconstitution after AHCT in non-Hodgkin lymphoma (NHL) and their correlations with clinical outcomes. In our prospective cohort study, we analyzed patterns of lymphocyte reconstitution and focused on T reg subsets for 41 patients who underwent AHCT for NHL between 2010 and 2016. Flow cytometry analysis was performed on blood samples collected prospectively at days +28, +60, and +100 post-AHCT. Patients' overall survival (OS) and progression-free survival (PFS) were correlated with Treg immune cell reconstitution. At day +28, Tregs comprised a median of 2.7% (range, 0.4% to 16.8%) of the total lymphocyte population. The proportion of proliferating Tregs (Ki67(+) Tregs) varied widely from 6.3% to 59.2% (median, 16.1%) of total Tregs and has a significant effect on post-transplantation outcomes. AHCT recipients with low levels of proliferating Tregs (ie, <16.1%, Ki67(+) Tregs) at 28 days had better 5-year OS compared to patients with high Ki67(+) Treg levels (75% versus 42%; P = .01). Higher levels of proliferating Tregs at day +28 post-AHCT were associated with higher mortality, with the most frequent cause of death due to lymphoma progression. This association suggests that immunosuppressive cellular reconstitution adversely impacts survival in AHCT recipients with NHL. (C) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:184.e1 / 184.e8
页数:8
相关论文
共 54 条
  • [1] Batorov Egor V, 2018, Oncotarget, V9, P27305, DOI 10.18632/oncotarget.25553
  • [2] Expansion of a restricted residual host Treg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation
    Bayer, Allison L.
    Chirinos, Jackeline
    Cabello, Cecilia
    Yang, Jing
    Matsutani, Takaji
    Malek, Thomas R.
    Levy, Robert B.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (12) : 3467 - 3478
  • [3] Host CD4+ CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT
    Bayer, Allison L.
    Jones, Monica
    Chirinos, Jackeline
    de Armas, Lesley
    Schreiber, Taylor H.
    Malek, Thomas R.
    Levy, Robert B.
    [J]. BLOOD, 2009, 113 (03) : 733 - 743
  • [4] Immune regulatory cell infusion for graft-versus-host disease prevention and therapy
    Blazar, Bruce R.
    MacDonald, Kelli P. A.
    Hill, Geoffrey R.
    [J]. BLOOD, 2018, 131 (24) : 2651 - 2660
  • [5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [6] Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies
    D'Arena, Giovanni
    Vitale, Candida
    Coscia, Marta
    Festa, Agostino
    Di Minno, Nicola Matteo Dario
    De Feo, Vincenzo
    Caraglia, Michele
    Calapai, Gioacchino
    Laurenti, Luca
    Musto, Pellegrino
    Di Minno, Giovanni
    Fenoglio, Daniela
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
  • [7] Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival
    Dean, R
    Masci, P
    Pohlman, B
    Andresen, S
    Serafino, S
    Sobecks, R
    Kuczkowski, E
    Curtis, J
    Maciejewski, J
    Rybicki, L
    Kalaycio, M
    Hsi, E
    Theil, K
    Bolwell, BJ
    [J]. BONE MARROW TRANSPLANTATION, 2005, 36 (12) : 1049 - 1052
  • [8] Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma
    Dhakal, Binod
    Veltri, Lauren Westfall
    Fenske, Timothy S.
    Eastwood, Daniel
    Craig, Michael D.
    Cumpston, Aaron
    Shillingburg, Alexandra
    Esselman, Jean
    Watkins, Kathy
    Pasquini, Marcelo C.
    D'Souza, Anita
    Hari, Parameswaran
    Kanate, Abraham Sebastian
    Hamadani, Mehdi
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1773 - 1780
  • [9] Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
    Di Ianni, Mauro
    Falzetti, Franca
    Carotti, Alessandra
    Terenzi, Adelmo
    Castellino, Flora
    Bonifacio, Elisabetta
    Del Papa, Beatrice
    Zei, Tiziana
    Ostini, Roberta Iacucci
    Cecchini, Debora
    Aloisi, Teresa
    Perruccio, Katia
    Ruggeri, Loredana
    Balucani, Chiara
    Pierini, Antonio
    Sportoletti, Paolo
    Aristei, Cynthia
    Falini, Brunangelo
    Reisner, Yair
    Velardi, Andrea
    Aversa, Franco
    Martelli, Massimo F.
    [J]. BLOOD, 2011, 117 (14) : 3921 - 3928
  • [10] Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
    DiPersio, John F.
    Micallef, Ivana N.
    Stiff, Patrick J.
    Bolwell, Brian J.
    Maziarz, Richard T.
    Jacobsen, Eric
    Nademanee, Auayporn
    McCarty, John
    Bridger, Gary
    Calandra, Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4767 - 4773